The angiogenic cytokine vascular endothelial growth factor (VEGF)-A plays a central role in both wound healing and tumor growth. In the skin, epidermal keratinocytes are a major source of this growth factor. To study the contribution of keratinocyte-derived VEGF-A to these angiogenesisdependent processes, we generated mice in which this cytokine was inactivated specifically in keratin 5-expressing tissues. The mutant mice were macroscopically normal, and the skin capillary system was well established, demonstrating that keratinocyte-derived VEGF-A is not essential for angiogenesis in the skin during embryonic development. However, healing of full-thickness wounds in adult animals was appreciably delayed compared with controls, with retarded crust shedding and the appearance of a blood vessel-free zone underneath the newly formed epidermis. When 9,12-dimethyl 1,2-benzanthracene was applied as both tumor initiator and promoter, a total of 143 papillomas developed in 20 of 23 (87%) of control mice. In contrast, only three papillomas arose in 2 of 17 (12%) of the mutant mice, whereas the rest merely displayed epidermal thickening and parakeratosis. Mutant mice also developed only 2 squamous cell carcinomas, whereas 11 carcinomas were found in seven of the control animals. These data demonstrate that whereas keratinocyte-derived VEGF-A is dispensable for skin vascularization under physiological conditions, it plays an important albeit nonessential role during epidermal wound healing and is crucial for the development of 9,12-dimethyl 1,2-benzanthracene-induced epithelial skin tumors.
INTRODUCTION
Vascular endothelial growth factor (VEGF)-A, first described as a vascular permeability factor and subsequently described as an endothelial cell-specific growth factor, is the founding member of a family of VEGFs that includes VEGF-B, VEGF-C, VEGF-D, and placenta growth factor [PlGF (1) ]. These additional VEGF family members share receptors with VEGF-A (2); both VEGF-D and PlGF can stimulate angiogenesis (3, 4) , whereas VEGF-B is only weakly mitogenic for blood vessel endothelial cells in vitro but appears to contribute to cardiac vessel development and function. VEGF-C seems mainly to be a growth factor for lymphatic endothelial cells (5) , although it might also play a role in vessel development because VEGF receptor 3-null mice die at midgestation, before the onset of lymphangiogenesis (6) . In addition, PlGF can form heterodimers with VEGF-A (7) and may regulate the activity of VEGF-A by competing for their common receptor, VEGF receptor 1 [Flt-1 (8) ]. VEGF-A is essential for blood vessel formation during embryonic development (9, 10) . In contrast, in the adult organism, where blood vessels are normally quiescent, VEGF-A is up-regulated in settings of increased vascular requirements, such as during the female reproductive cycle, and during tissue repair and tumor growth (for reviews, see Refs. 1, 2, and 11).
In the skin, the main source of VEGF-A is the epidermal keratinocyte. Keratinocytes constitutively express VEGF-A protein (12, 13) , and a marked up-regulation of VEGF-A is observed in these cells during wound healing (14) and inflammatory skin diseases (15) (16) (17) . VEGF-A is also abundantly expressed in epithelial skin tumors (13, 18) . However, other sources can contribute to the overall levels of VEGF-A in the skin: the dermal extracellular matrix harbors heparinbound VEGF-A that can be liberated by proteases activated in a wound bed (reviewed in Ref. 2) , and dermal macrophages, migrating into a wound, express VEGF-A mRNA (14) . In addition, other cytokines, such as PlGF (4), fibroblast growth factor 2 (19) , and the angiopoietins and thrombospondins participate in the regulation of angiogenesis in the skin (20, 21) . Finally, in the setting of tumormediated angiogenesis, VEGF-A promoter activity was found to be induced in tumor stromal cells (22) , suggesting that tumors can regulate angiogenic activity in nontransformed peritumoral cells.
Thus, to examine the relative contribution that keratinocyte-derived VEGF-A makes to pathophysiological angiogenesis in the skin, mice in which VEGF-A is inactivated specifically in epidermal and follicular keratinocytes were generated by means of the Cre-lox-P system (23) . Studies on the healing of skin wounds and susceptibility to carcinogen-induced papilloma formation reveal that, depending on the setting of the angiogenic stimulus, epidermal keratinocytes contribute to quite different degrees to blood vessel formation.
MATERIALS AND METHODS

Generation of VEGF-A-Deficient Mice
A male mouse bearing the cre recombinase transgene under the control of the keratin 5 (K5) promoter [K5-cre ϩ (24) ] was mated to females homozygous for the floxed VEGF-A allele [VEGF-A loxP/loxP (25) ; both mouse lines are from a C57Bl/6 ϫ 129 mixed background]. VEGF-A ⌬k5-cre/ϩ F 1 heterozygotes (that have deleted one VEGF-A allele specifically in K5-cre-expressing cells) were bred to mice homozygous for the VEGF-A loxP/loxP allele. Offspring from these matings that have deleted both of the floxed VEGF-A alleles specifically in K5-cre-expressing cells (VEGF-A ⌬k5-cre/⌬k5-cre ) are designated as mutant mice, and age-and sex-matched VEGF-A loxP/loxP animals (littermates as far as possible) served as controls. Unless otherwise noted, all mice were 7-8 weeks of age when analyzed or used for experiments.
PCR and Southern Blotting
PCR and Southern blotting were performed on genomic DNA from tail epidermal sheets prepared by the trypsin flotation method [1 h at 37°C, 0.25% trypsin (Difco 1:250, Detroit, MI) in PBS]. Primers and reaction conditions to detect the LoxP sites, the cre transgene, and the recombination efficiency at the LoxP sites of the floxed exon 3 of VEGF-A have been described previously (25) . Here, we have modified the PCR conditions for the detection of recombination by using the primer pair VEGFc5R.2 and mVEGF322.F ( Fig. 1 ; Ref. 25) to detect excision of the entire VEGF-A exon 3 by PCR (1 cycle of 95°C for 5 min; 30 cycles of 95°C for 1 min, 58°C for 1 min, and 72°C for 2 min; and 1 cycle of 72°C for 5 min). To confirm the deletion of VEGF-A exon 3 by Southern blotting, genomic DNA was digested with ACC I (Roche, Vienna, Austria), separated by agarose gel electrophoresis, and probed with a PCR fragment generated by the primer pair VEGFc5R.2 and mVEGF322.F that spans exon 3 (Fig. 1A) .
Tissue Preparation and Cell Culture
To detect VEGF-A production by epidermal keratinocytes, single cell suspensions were prepared from tail or trunk skin of adult or neonatal mice, respectively, by protease digestion. The cells were suspended in low-calcium growth medium (26) and plated at about 80% confluence in Costar 12-well plates coated with collagen IV (Vitrogen, Palo Alto, CA). After initial overnight incubation, adherent cells were cultured for an additional 48 h, and VEGF-A concentrations were assayed by ELISA in cleared supernatants, using a commercial murine VEGF-A ELISA (R&D, Wiesbaden-Nordenstadt, Germany). For some experiments, epidermal sheets prepared from split ears by flotation on dispase solution were used instead of single cell suspensions. Genomic DNA was prepared for quantitation of cell material in each well.
Histology
Rat antimurine CD31 monoclonal antibody (PharMingen, San Diego, CA) was used to detect blood vessels in either acetone-fixed frozen sections (10 g/ml) or dermal sheet preparations from ears (25 g/ml). The biotinylated secondary antibody for CD31 staining (Amersham, Little Chalfont, United Kingdom) was used for frozen sections at a dilution of 1:200, whereas for dermal sheets, a phycoerythrin-conjugated secondary antibody (Alexa-Fluor; Molecular Probes, Eugene, OR) was used (4 g/ml, final concentration). To detect apoptotic cells, 4-m sections of formalin-fixed paraffin-embedded tissues were stained with rabbit antibody to active caspase 3 (R&D Systems, Minneapolis, MN), whereas macrophages were identified with a goat antibody to Mac-1 (anti-integrin ␣ M ; Santa Cruz Biotechnology, Heidelberg, Germany). Biotinylated antirabbit and antigoat secondary antibodies were from Vector (Burlingame, CA) for immunohistochemistry or from Molecular Probes (Alexa-Fluor488 or Alexa-Fluor546) for immunofluorescence. Binding of antibodies for immunohistochemistry was visualized with the horseradish peroxidase-strept-ABC from DAKO (Glostrup, Denmark). Additional sections were also stained with H&E or with chloroacetate esterase by standard procedures.
For whole mount blood vessel preparations, dermal sheets recovered after flotation of split ears on 3.8% ammonium isothiocyanate at 37°C for 30 -40 min were fixed in acetone for 10 min at 4°C. They were then blocked with a mixture of 10% normal goat serum and 2% BSA in PBS for 60 min, incubated with anti-CD31 antibody overnight at 4°C, and washed twice, and bound antibody was detected by incubation with secondary antibody for 60 min at room temperature. Finally, the preparations were mounted with Fluoprep (bioMérieux, Marcy d'Etoile, France) for microscopic evaluation.
Wounding Experiments
Three male mice/genotype and time point were depilated with a commercial cream (Veet; Reckitt Benckiser, Mannheim, Germany) 1-2 days before wounding. The mice were anesthetized with 2.5% Avertine (tribromoethyl alcohol/tertiary amyl alcohol; Sigma), and two 6-mm full-thickness punch biopsy wounds were set by folding the back skin and punching through 2 thicknesses of skin. Wounds were measured in two dimensions with handyman's calipers (Metrica) and photographed at the indicated times. At harvest, the animals were sacrificed by chloroform inhalation, and the wounds were excised, bisected, and frozen in OCT compound (Sakura, Zoeterwoude, the Netherlands).
Carcinogenesis Protocol
A concentration of 50 g/50 l 9,12-dimethyl 1,2-benzanthracene (DMBA; Sigma) was applied to the backs of 28 VEGF-A loxP/loxP and 20 VEGF-A ⌬k5-cre/⌬k5-cre mice (1-4 days old) once a week for 17 weeks. The carcinogen was diluted in ethanol for the first eight applications, and then diluted in acetone, and mice were shaved with clippers as needed. Papillomas were scored when they reached a size of 1 mm and had been present for 1 week or more, and at sacrifice, samples of skin and/or tumors were embedded in OCT or fixed in 4.5% formalin and embedded in paraffin (22 control and 13 mutant mice survived to the end of the experiment). Dysplasia was classified in two grade categories. Low-grade intraepithelial dysplasia and reactive simulants, which are not reliably distinguishable from low-grade dysplasia, i.e., atypia, indefinite for dysplasia, consisted of basally located cells with slightly to moderately enlarged or hyperchromatic nuclei involving less than one-half of the epithelium (grade I). By contrast, high-grade dysplasia was composed either of immature cells with distinctly hyperchromatic nuclei involving more than half of the epithelium or of larger basal cells with marked atypical nuclei 
Morphometric Analyses of Blood Vessels
Normal Skin. The blood vessel density within 40 m of the basement membrane of healthy adult skin was assessed in CD31-stained tissue sections by manually counting multicellular and single-celled stained structures over the whole length of the specimen and converting to number of vessels/mm (six control and nine mutant mice were analyzed). Blood vessels immediately adjacent to hair follicles were not included in the counts, and mice in anagen were omitted from the analysis.
Wounds. CD31-stained tissue sections were photographed with an RT slider spot digital camera (Visitron, Puchheim, Germany) attached to an Olympus Provis microscope. Calibration of each image and assessment of distances were performed with the Metamorph Imaging System, Version 4.5r3. The distances of blood vessels from the neoepidermis were measured across the entire width of six wounds (on three animals) per genotype for day 8 and 3-4 wounds per genotype for day 23.
Tumors and Tumor-Free, DMBA-Treated Skin. Images of CD31-stained tissue sections were captured as described above, and the relative area of blood vessels in the tumor stroma, in the dermis between the rete ridges of hyperplastic skin, or within 100 m of the basal membrane in normal skin was calculated using an area tool in Adobe Photoshop 5.5 software. Two squamous cell carcinomas (SCCs), three papillomas (all on different mice), tumor-free DMBA-treated skin from three control mice, and DMBA-treated skin from six mutant mice, with 2-3 images/sample, were used for quantitation.
Student's t test was used to analyze the statistical significance of all groups compared.
RESULTS
Loss of VEGF-A Exon 3 Inhibits VEGF-A Secretion by Epidermal Keratinocytes.
Mice were genotyped by PCR amplification of tail DNA. (Fig. 1, A and B) . Cre-specific primers detect the presence of the cre transgene (Fig. 1B, top Attempts to demonstrate decreased VEGF-A protein production in the mutant mice in vivo by immunohistochemical analysis of normal skin and wounds were unsuccessful; both mutant and control mice stained equally well (data not shown). Because all of the commercially available antibodies are directed against the NH 2 terminus of the protein, they must recognize a truncated product in the mutant mice. However, Fig. 1D shows that using a sensitive ELISA assay, no VEGF-A protein could be detected in the supernatants of cultured epidermal cells from various body sites of VEGF-A ⌬k5-cre/⌬k5-cre mice. Note that of the four ear preparations, two were cultures of dispersed epidermal cells, and two were cultures of intact epidermal sheets from split ears. Thus, K5-cre-mediated excision of VEGF-A exon 3 is efficient, and epidermal keratinocytes of mutant mice do not secrete detectable amounts of VEGF-A into culture medium. Furthermore, no compensatory up-regulation of PlGF protein was found by ELISA in similar supernatants, nor was compensatory up-regulation of PlGF mRNA found in epidermal cells by quantitative reverse transcription-PCR (not shown).
Mutant Mice Are Grossly Normal and Exhibit Only a Slight Reduction in Subepidermal Capillary Density. Mutant pups were born at approximately the expected Mendelian frequencies, as long as male K5-cre ϩ mice were used for transgene transmission. In contrast, when female VEGF-A ⌬k5-cre/⌬k5-cre mice were used for breeding, they bore fewer young than controls, and all offspring lacked the K5-cre transgene. Presumably, germ-line excision of the floxed VEGF-A allele due to global zygotic gene activation (27) results in lethality at midgestation (9, 10) .
Mutant newborn pups were healthy and had no obvious skin defects, but mutant males grew more slowly than controls and weighed 10 -20% less between weeks 2 and 8 of age [P Ͻ 0.05 at weeks 2-3 and 5-8 (data not shown)]. Thereafter, all male mice were of similar weight. Interestingly, mutant females were significantly smaller only at 5-6 weeks and Ͼ12 weeks of age. For each genotype and time point, a minimum of 3 mice (up to a maximum of 19 mice, depending on availability) were weighed. Although angiogenesis and/or VEGF-A production by keratinocytes has been reported to be regulated in concert with the hair cycle (28, 29) , we observed that macroscopically, the onset of the first hair cycle occurred simultaneously in mutant and control mice, and no overt hair abnormalities were A preliminary histomorphometric analysis of the first hair cycle revealed that, compared with controls, hair follicles in mutant mice entered catagen earlier, and there was a reduced interfollicular microvessel density between days 6 and 19. 6 However, a detailed analysis of the hair cycle in these mice is beyond the scope of the present study.
Whole mount CD31 staining of normal ear dermis revealed no apparent differences in densities of larger blood vessels between mutant and control mice ( Fig. 2A) . However, enumeration of CD31-stained microvessels in frozen sections revealed a small but significant reduction in the number of capillaries lying within 40 m of the basement membrane (Fig. 4K) in the mutant mice compared with controls (Fig. 2B) . Thus, the absence of keratinocyte-derived VEGF-A has only a marginal effect on the vasculature of quiescent skin.
Wound Healing Is Retarded in VEGF-A ⌬k5-cre/⌬k5-cre Mice. Because angiogenesis is necessary for effective tissue repair, we asked whether the lack of VEGF-A production by epidermal keratinocytes in VEGF-A ⌬k5-cre/⌬k5-cre mice would affect the healing of skin wounds. Fig. 3A shows that the initial phase of clotting and crust formation proceeded similarly in both mutant and control groups. However, after about day 6, crust shedding stagnated in mutant mice, and wounds were still covered with a crust by day 12, a time at which control wounds had almost healed. Fig. 3B shows that 50% of the crusts are shed by day 11 after wounding in the VEGF-A loxP/loxP mice compared with day 15 in the mutant mice, and mutant wounds are significantly larger at days 12 and 15 (Fig. 3C) .
Because wound healing during the first 9 days progressed comparably in both mutant and control mice, the wounds were examined microscopically at time points just preceding the observed macroscopic differences (days 6 -10). At day 6, wounds in both groups appeared similar: newly formed epidermis (asterisk) can be seen dissecting under the fibrin clot (Fig. 4, A and B) , and the granulation tissue of both groups displays rich neovascularization, as visualized by CD31 staining. By day 8, blood vessel density was still high in the hypercellular granulation tissue at the wound center (Fig. 4, C and D) but had started to decline at the wound periphery, and an avascular zone had appeared adjacent to the basement membrane of the neo-6 L. Mecklenburg and R. Paus, unpublished observations. epidermis in the mutant mice, but not the control mice (Fig. 4, E and F, wound margins of same wounds as shown in Fig. 4, C and D) . Apart from the lack of blood vessels, this area appeared similar in both groups of mice, and was composed of highly cellular, fibronectin-rich granulation tissue in the earlier wounds (up to day 10), which was replaced by relatively acellular collagenous dermis by day 14 (data not shown). This blood vessel-free zone is retained in the mutant mice at all subsequent time points examined (at 2-day intervals up to day 23 after wounding; days 10 and 23 are shown, Fig. 4, G-J) .
Histomorphometric analysis of the location of blood vessels revealed that these lie significantly further away from the basal membrane in mutant mice compared with controls (days 8 and 23 are shown as representative of open and completely healed wounds). Vessels in unwounded skin, however, were situated at similar distances from the basal membrane in both groups (Fig. 4K) .
Because macrophages can also secrete VEGF-A and are often recruited to sites of active angiogenesis, we examined the distribution of Mac-1-positive cells in wounds from day 6 to day 19 and in uninvolved peri-wound skin. Whereas similar numbers of Mac-1-positive cells were found in the upper dermis of peri-wound skin (2.95 Ϯ 1.2 and 2.50 Ϯ 0.6 cells/mm epidermis of mutant and control mice, respectively; P Ͼ 0.05; n ϭ 2 mice; 15 fields of view/genotype), their numbers varied greatly in wounds, appearing to be more numerous in mutant granulation tissue of day 6 wounds (261.0 Ϯ 87.5 and 90.4 Ϯ 25.2 cells/mm 2 , respectively; P Ͻ 0.005; n ϭ 4 mutant and 3 control wounds). In healed wounds at days 14 -19, Mac-1-positive cells were mostly in the deeper dermis in all mice, with occasional cells near the basal membrane (and thus in the avascular zone in the case of mutant mice), but there was no apparent correlation with the presence of keratinocyte-derived VEGF-A or with blood vessel density. Wound healing is thus retarded in the mutant mice and associated with the appearance of a blood vessel-free zone adjacent to the neoepidermis.
Papilloma Development Is Abrogated in DMBA-Treated VEGF-A ⌬k5-cre/⌬k5-cre Mice. In a preliminary experiment, adult female mice of the strain used in this study (C57Bl6 ϫ 129) were almost completely refractory to squamous papilloma development induced by initiation with 2 ϫ 50 g of DMBA and promotion with 5 g of phorbol 12-myristate 13-acetate for 20 weeks (data not shown). However, in subsequent experiments, commencing DMBA treatment when mice were 1-4 days of age and continuing for 17 weeks, 1-20 papillomas/mouse developed. A total of 143 papillomas developed in 20 of 23 (87%) control animals, whereas only 3 papillomas were found in 2 of 17 mutant mice (Table 1 ; Fig. 5 A) .
Male VEGF-A loxP/loxP mice were more sensitive to papilloma induction than VEGF-A loxP/loxP females: they developed more lesions, that appeared earlier; and all of the male (but only 70% of the female) control mice had papillomas for at least some of the time (Fig. 5B) . Many of the mice (both mutant and controls) appeared moribund at about 20 weeks after the start of DMBA application, and histological analysis of spleen, liver, and lung of these mice revealed lymphomalike infiltrates (data not shown).
Histological examination of H&E-stained, formalin-fixed sections of the tumors of control mice revealed that the majority of skin lesions were typical squamous papillomas (Fig. 6, A and C (Fig. 6, B and D) , and only 1 carcinoma was identified in each of 2 of the mutant mice. Both mutant and control mice displayed epidermal hyperplasia in the area of DMBA application, but these changes were much more severe in the mutants (Fig. 5A ) than in the controls (data not shown). Indeed, the treated skin of mutant mice showed evidence of either abundant inflammatory cells (Fig. 6, G and  I) , or a hyperproliferative epidermis and a parakeratotic stratum cor- (Fig. 6, H and J) . The lack of keratinocyte-derived VEGF-A may allow enhanced binding of keratinocyte-derived PlGF to VEGF-A receptor 1, resulting in an increase in inflammatory cell recruitment to the DMBA-treated skin (31) , which could exacerbate epidermal hyperproliferation (32) . Control mice showed low-to highgrade dysplasia in papillomas and carcinomas, respectively ( Fig. 6C,  arrows; Fig. 6D, most cells) . In contrast, although 12 of 13 mutant mice that were examined histologically displayed epidermal hyperplasia, even the most hyperplastic sections were free of evidence of neoplastic change and only showed evidence of low-grade dysplasia or were indefinite for dysplasia (Fig. 6J) . p53 protein was only detected in one specimen (from a mutant mouse; data not shown), in agreement with previous findings that this is not the primary mutation induced by DMBA.
CD31 staining of frozen sections revealed an ample supply of large blood vessels in intimate contact with the basal keratinocyte layers of the tumors in the control mice (Fig. 6, E and F) . In contrast, the blood vessels situated near the hyperplastic epidermis in the mutant mice were thin and delicate-looking (compare Fig. 6E with Fig. 6, K and L) . Quantitative histomorphometric analysis of blood vessel area in the tumor stroma of control mice or the dermis between the psoriasiform hyperplastic epithelial projections of mutant mice showed that the former occupied a significantly larger area than the latter and was in fact similar to the area occupied by blood vessels in uninvolved control dermis (Fig. 6M ). In addition, large s.c. vessels emanating from papillomas in the control mice (Fig. 7 , A and C) were missing underneath the treated skin of the mutant mice (Fig. 7, B and D) .
Inflammatory cells are attracted to sites of hyperplasia and dysplasia and are thought to contribute to the angiogenic switch (33), a prerequisite for tumor growth. Thus, to examine whether a reduced infiltration of inflammatory cells could contribute to the decreased blood vessel density in the mutant mice, sections of DMBA-treated skin, as well as SCCs and papillomas from controls, were stained with chloroacetate esterase to detect mast cells and neutrophils (2 DMBAtreated, tumor-free skin samples; 2 papillomas and 2 SCCs from control mice; and 6 DMBA-treated skin samples from mutant mice) and Mac-1 to detect macrophages (4 DMBA-treated, tumor-free skin samples; 2 papillomas and 2 SCCs from control mice; and 7 DMBAtreated skin samples from mutant mice). Normal-appearing DMBAtreated skin of both genotypes harbored few cells of either type (4.0 Ϯ 0.2 compared with 6.5 Ϯ 1.5 mast cells/mm for control and mutant mice, respectively). Many mast cells (37 Ϯ 16 cell/mm) were, however, located adjacent to the hyperplastic epidermis of mutant mice, but not near SCCs (3.8 Ϯ 2.1 cells/mm), papillomas, or moderately hyperplastic epidermis of controls (12 Ϯ 10 cells/mm; P Ͻ 0.0001). Macrophages were plentiful in the inflamed dermis of mutant mice and, as expected, in SCCs and papillomas of controls (data not shown).
The reduced blood vessel density found in the mutant mice could result in a reduction of nutrient supply to the epidermis, leading to increased cell death, thereby preventing papilloma outgrowth. However, when we tested for the presence of apoptotic cells by immunostaining for activated caspase 3, no significant difference was found between hyperproliferative epidermis of mutant mice compared with the DMBA-treated skin of controls (1.14 Ϯ 1.27 and 1.22 Ϯ 1.24 cells/mm epidermis, respectively; n ϭ 5 control and 7 mutant mice).
Thus, virtually no tumors form in DMBA-treated skin of VEGF-A ⌬k5-cre/⌬k5-cre mice, and blood vessel density does not increase, despite the presence of dermal cells that could provide angiogenic factors. Furthermore, the lack of tumor formation is not associated with increased apoptosis in the carcinogen-treated skin.
DISCUSSION
The conditional inactivation of VEGF-A specifically in epidermal keratinocytes has allowed us to examine the functional contribution of VEGF-A produced by these cells to angiogenesis during wound healing and chemical carcinogenesis. VEGF-A is essential for embryonic blood vessel development (9, 10) , but the lack of any major change in the dermal vasculature of VEGF-A ⌬k5-cre/⌬k5-cre mice demonstrates that keratinocyte-derived VEGF-A is not essential for the establishment of the skin vasculature during embryogenesis and can probably be functionally substituted by either VEGF-A from other sources, such as Schwann cells of peripheral nerves (34) or other angiogenic factors, such as transforming growth factor ␤1, fibroblast growth factor 2, and the angiopoietins (35) .
induces many tumors in VEGF-A loxP/loxPb but not in VEGF-
VEGF-A is an important factor in angiogenesis during wound healing and is strongly up-regulated in keratinocytes in skin wounds (14) . However, the data presented in this study suggest that other sources in the early wound bed can substitute for keratinocyte-derived VEGF-A, for example, liberation from extracellular matrix stores by platelet-secreted proteases (36) or secretion by infiltrating macrophages. In addition, other proangiogenic cytokines, such as the fibroblast growth factors, platelet-derived growth factor, transforming growth factor ␤, and interleukin 8 (reviewed in Ref. 37) or keratinocyte-derived PlGF (38) and fibroblast growth factor 2 (39) could contribute to blood vessel formation in the early wound bed. By contrast, during the completion of wound re-epithelialization, as evidenced by crust shedding (40, 41) , keratinocytes may become the most important source of VEGF-A. Thus, in its absence, negative regulators of angiogenesis, such as thrombospondin-2 (20) , which increases in the later stages of wound healing (42) , could predominate, leading to capillary cell death and the formation of an avascular zone. In addition, VEGF-A acts as a chemotactic factor for endothelial cells (43) , so that its absence in mutant mice might lead to decreased migration toward the epidermis, again resulting in a blood vessel-free zone. Keratinocyte-derived VEGF-A is therefore dispensable for the early phases of granulation tissue formation and angiogenesis but plays a role in the later phase of wound healing, namely, the reconstitutio ad integrum of the subepidermal capillary plexus. Furthermore, the lack of subepidermal capillaries implies that the action of keratinocyte-derived VEGF-A, be it survival or chemotactic, is targeted to the endothelial cells of these capillaries only and does not attract infiltrating macrophages, whose distribution during the course of healing did not correlate with the presence of keratinocyte-derived VEGF-A. Furthermore, these macrophages cannot substitute for keratinocyte-derived VEGF-A in the reconstitution of the subepidermal capillary plexus.
In contrast to the partial independence from keratinocyte-derived VEGF-A for normal skin biology and wound healing, our data demonstrate that the formation of DMBA-induced epidermal tumors crucially depends on VEGF-A produced by keratinocytes. It is well established that tumor growth above a certain size is dependent on angiogenesis and that VEGF-A is important for this process. Specifically, in skin, VEGF-A is up-regulated in premalignant papillomas (44) , and targeted overexpression of VEGF-A to murine epidermis predisposes mice to the development of tumors (45) . Furthermore, an increase in VEGF-A expression correlates directly with increased activity of oncogenes important in skin carcinogenesis (44, 46) . Conversely, in a model of murine pancreatic ␤-cell carcinogenesis, loss of VEGF-A expression leads to a reduction of tumor numbers and size (47) . In the model of skin carcinogenesis used in the present study, lack of VEGF-A expression in DMBA-treated mutant mouse skin did not merely result in smaller or fewer papillomas than in control animals but virtually abrogated papilloma development altogether. Moreover, dysplastic changes, although obvious in papillomas and SCCs of control mice, were at best indefinite, even within the most hyperplastic epidermis of the mutants, and blood vessel density was comparable with that of normal skin. Thus, in the multistage model of skin carcinogenesis, in which activation of oncogenes results in progression from hyperplasia to dysplasia with concomitant angiogenesis and finally to invasive carcinomas, keratinocyte VEGF-A-null mice are arrested at the predysplastic stage of hyperplasia. Dysplastic cells may have an increased metabolic rate compared with normal cells (48) , and the increased vascularization induced by VEGF-A could provide the nutrients necessary for their survival and for the exophytic growth typical of papillomas. However, our finding that similar numbers of apoptotic cells were present in both hyperproliferative epidermis of mutant mice and tumor-free DMBA-treated skin of control mice argues against this interpretation and suggests that other mechanisms are involved in the suppression of tumor outgrowth in the absence of VEGF-A.
Mast cells have been suggested to "kick-start"' the angiogenic switch in the early stages of tumor development (33) , perhaps providing the angiogenic stimulus even before the hyperplastic tissue itself. However, the finding that ample mast cells present in the vicinity of hyperplastic epidermis did not result in increased angiogenesis and papilloma development suggests that angiogenic factors produced by these cells are by themselves insufficient to induce the angiogenic switch.
The dependence of papilloma formation on keratinocyte-derived VEGF-A has been confirmed in a different mouse model, in which K5-SOS mice, which develop papillomas with 100% penetrance, were crossed to the VEGF-A ⌬k5-cre/⌬k5-cre mice described here. Double transgenic mice bearing the K5-SOS and cre transgenes and thus lacking keratinocyte-derived VEGF-A were retarded in papilloma formation compared with K5-SOS controls. 7 Nevertheless, the mechanism underlying the almost complete abrogation of tumor formation deserves further study. For instance, lymphangiogenesis, which is also important for tumor formation and has recently been shown to be regulated by VEGF-A (49), has not yet been examined in this model, and a study of the behavior of inflammatory cells in the absence of VEGF-A during tumorigenesis may shed light on the chemotactic stimuli that these cells need to migrate.
In summary, we have investigated the contribution of epidermal keratinocyte-derived VEGF-A to two important settings of angiogenesis in the adult, namely, wound healing and tumor formation in the skin. We show that firstly, keratinocyte-derived VEGF-A is essential for re-establishment of the subepithelial capillary plexus in the late phase of wound healing and that in its absence, wound healing is substantially retarded. Promotion of VEGF-A secretion or application of VEGF-A-containing medication (reviewed in Ref. 50 ) may thus be an effective therapy in both the late and early phases of poorly healing wounds. Secondly, the lack of dysplastic cells in carcinogen-treated skin in the absence of VEGF-A suggests that this cytokine is not only important for growth of advanced tumors but might also be involved in the early phase of progression from the hyperplastic to the dysplastic stage.
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